Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A
lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Your browser is not supported
Switch to Chrome, Edge, Firefox or Safari
This report presents information about Medicaid coverage of medication-assisted treatment for opioid and alcohol dependence. It covers treatment effectiveness and cost effectiveness. The report also offers examples of innovative approaches in Vermont, Massachusetts, and Maryland.
Medicaid: Financing Meds to Treat Alcohol, Opioid Use
(PDF | 1.87 MB)
This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.
This report provides a snapshot of key aspects of behavioral health, serious mental illness, suicidal thoughts, and mental illness, substance use disorders, or both. The information is based on selected determinants of health, including race and ethnicity, income level, geography, and health insurance status.
This guide informs clinicians about medications for opioid use disorder treatment, including side effects, drug interactions, and take-home doses. It discusses patient counseling, associated medical issues, hepatitis C evaluation, drug testing, and pregnant women.
This handbook provides guidance on using the web-based, multimedia tool Decisions in Recovery: Medications for Opioid Addiction. This handbook and the web-based tool offers information about medication-assisted treatment. Both resources help people living with opioid use disorder compare treatment options and discuss their preferences with a provider.
The National report presents indicators as measured through the 2019 National Survey on Drug Use and Health and the National Survey of Substance Abuse Treatment Services. State reports provide a snapshot of substance use and mental health in the United States.
This advisory gives an overview of extended-release injectable naltrexone for people with opioid dependence. It discusses how it differs from other medication-assisted treatments, safety concerns, and patients most likely to benefit.
